Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,323 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 |
| clinicaltrials |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
| NCT02279732 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | completed | Phase 3 | 342 | Bristol-Myers SquibbINDUSTRY | 6 | Aug 28, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT01877083 | Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung | completed | Phase 2 | 25 | Eisai Inc.INDUSTRY | 5 | Aug 13, 2019 | clinicaltrials |
| NCT01953913 | Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation | completed | Phase 3 | 542 | Boehringer IngelheimINDUSTRY | 5 | Aug 12, 2019 | clinicaltrials |
| NCT02751879 | Real World Data on Gi(l)Otrif® Dose Adjustment | completed | — | 228 | Boehringer IngelheimINDUSTRY | 13 | Aug 8, 2019 | clinicaltrials |
| NCT01055496 | Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | completed | Phase 1 | 103 | PfizerINDUSTRY | 9 | Aug 2, 2019 | clinicaltrials |
| NCT00414271 | Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer | completed | Phase 2 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT01309633 | Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 80 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | completed | Phase 3 | 508 | Boehringer IngelheimINDUSTRY | 38 | Jul 18, 2019 | clinicaltrials |
| NCT02281019 | SpyGlass AMEA Registry | completed | — | 526 | Boston Scientific CorporationINDUSTRY | 10 | Jul 10, 2019 | clinicaltrials |
| NCT01543776 | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | University of ChicagoOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT01289041 | BKM120 as Second-line Therapy for Advanced Endometrial Cancer | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 13 | May 30, 2019 | clinicaltrials |
| NCT03938012 | Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma | unknown | — | 80 | National University Hospital, SingaporeOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT01953003 | Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 112 | Pierre Fabre MedicamentINDUSTRY | 3 | May 2, 2019 | clinicaltrials |
| NCT03552458 | Effects of Probiotics in Preventing Oral Mucositis | unknown | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT00282100 | Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma | unknown | Phase 2 | 40 | Tan Tock Seng HospitalOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | unknown | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02409576 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas(NKEXPSARC) | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia | suspended | Phase 1 | 20 | National University Health System, SingaporeOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03784040 | Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.(da VINci) | unknown | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00735917 | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | Apr 2, 2019 | clinicaltrials |
| NCT01685138 | LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 26, 2019 | clinicaltrials |
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
| NCT01512758 | A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 36 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01226576 | Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study | completed | N/A | 8 | InSightecINDUSTRY | 5 | Mar 13, 2019 | clinicaltrials |
| NCT00387205 | Study To Assess Long Term Safety Of Pazopanib | completed | Phase 1 | 188 | Novartis PharmaceuticalsINDUSTRY | 4 | Mar 6, 2019 | clinicaltrials |
| NCT02131155 | LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | terminated | Phase 3 | 36 | Boehringer IngelheimINDUSTRY | 4 | Mar 1, 2019 | clinicaltrials |
| NCT00465842 | Protein Biomarker in Hepatocellular Carcinoma | terminated | — | 211 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00899756 | Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer | completed | — | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT00465907 | Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT00484601 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT02605044 | Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer | terminated | Phase 3 | 123 | AB ScienceINDUSTRY | 3 | Feb 11, 2019 | clinicaltrials |
| NCT03671382 | Communication During Medical Consultations in Singapore -Pilot(TEAMS-pilot) | completed | N/A | 104 | Duke-NUS Graduate Medical SchoolOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT00769600 | Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC | terminated | Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 1, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 43 | Arbutus Biopharma CorporationINDUSTRY | 6 | Jan 16, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | completed | Phase 3 | 326 | PfizerINDUSTRY | 20 | Jan 9, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT02391116 | Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 67 | BayerINDUSTRY | 10 | Jan 4, 2019 | clinicaltrials |
| NCT02269943 | Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 36 | CelgeneINDUSTRY | 9 | Dec 12, 2018 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials